Abstract
Scleroderma — or systemic sclerosis — is one of the most relentless diseases in rheumatology. Not because it is the most common, but because of what it does: it slowly replaces living tissue with scar. Skin that should be supple becomes leathery and rigid. Lungs fill with fibrotic matrix. Blood vessels narrow and obliterate. The body’s own repair machinery turns against it, laying down collagen it cannot stop and cannot reverse.
Decades of research have identified the molecular culprits with reasonable precision. Transforming growth factor-beta (TGF-β). Connective tissue growth factor (CTGF). Activin A. The SMAD signaling cascade. Yet despite this knowledge, no therapy approved to date has consistently halted — let alone reversed — the fibrotic process in scleroderma. Most treatments suppress inflammation. None switch off the fibrotic program at its source.
Follistatin, a naturally occurring protein the body produces itself, may represent one of the most underappreciated tools in this fight. And gene therapy — delivering a sustained, self-renewing source of follistatin — may be the key to unlocking its full therapeutic potential.
What Is Follistatin?
Follistatin is an endogenous glycoprotein — a molecule your body makes — whose primary job is to act as a molecular sponge for members of the TGF-β superfamily, most notably Activin A and myostatin. It binds these proteins with extraordinary affinity and neutralizes their activity at the receptor level, before they can trigger the downstream signaling cascades that drive inflammation and fibrosis.
Follistatin at a Glance
- Endogenous glycoprotein produced naturally in multiple tissues including liver, ovary, pituitary, and skin fibroblasts
- Binds Activin A, Activin B, myostatin, and GDF-11 with high affinity — neutralizing their bioactivity
- Works upstream of the SMAD2/3 signaling pathway — blocking fibrogenic signal transduction before it begins
- Expressed in wound healing responses: upregulated when tissue repair is active, downregulated in chronic fibrotic states
- Anti-inflammatory, anti-fibrotic, and pro-regenerative — three therapeutic properties in one endogenous molecule
What makes follistatin particularly compelling is that its therapeutic targets are not peripheral players in scleroderma — they are central ones. Activin A is elevated in the serum and tissue of systemic sclerosis patients. Myostatin drives fibroblast activation and muscle wasting. Both signal through the same SMAD2/3 axis that TGF-β uses. Follistatin silences all of them.
The Fibrotic Cascade in Scleroderma: Where Follistatin Intervenes
To understand why follistatin matters in scleroderma, it helps to understand the cascade it interrupts. The fibrotic process in systemic sclerosis is not a simple linear pathway — it is a self-amplifying loop in which multiple signals reinforce each other.
The TGF-β / Activin A Axis
TGF-β1 is the master regulator of fibrosis in scleroderma. Its serum levels are elevated in patients and correlate with disease activity. But TGF-β does not act alone: it stimulates surrounding cells to produce Activin A, which then activates the same SMAD2/3 signaling pathway through its own receptors. In effect, Activin A amplifies TGF-β signaling in parallel, through a separate receptor system.
This parallel amplification is a major reason why blocking TGF-β alone has proven insufficient in clinical trials. When you suppress TGF-β, Activin A continues driving the same downstream fibrogenic program. Follistatin addresses both arms simultaneously — without touching the TGF-β receptor directly, and therefore without the serious immune and wound-healing side effects that have plagued TGF-β antagonists in development.
The Myostatin Connection
Myostatin — another TGF-β superfamily member and primary follistatin target — promotes fibroblast activation and drives the replacement of muscle tissue with fibrous matrix. In scleroderma, where both cutaneous fibrosis and muscle involvement are common, myostatin inhibition through follistatin provides an additional anti-fibrotic vector, complementary to its effects on Activin A.
| Signal | Effect in Scleroderma | Follistatin Action |
|---|---|---|
| TGF-β1 | Master fibrogenic driver; activates myofibroblasts, drives collagen deposition | Indirect: blocks Activin A amplification of TGF-β downstream signaling |
| Activin A | Elevated in SSC; amplifies SMAD2/3 signaling; promotes fibroblast activation and inflammation | Direct: binds Activin A with high affinity; neutralizes receptor binding |
| Myostatin | Drives muscle fibrosis and wasting; activates pro-fibrotic fibroblast phenotypes | Direct: binds and neutralizes myostatin — reduces fibroblast activation |
| SMAD2/3 pathway | Transcription of collagen genes, ECM proteins, and pro-fibrotic cytokines | Suppressed upstream: less Activin A / myostatin signaling → less SMAD2/3 activation |
| Inflammatory cycle | Activated immune cells produce TGF-β and Activin A, sustaining the fibrotic loop | Anti-inflammatory: reduced Activin A → reduced immune activation and cytokine amplification |
What the Research Shows
The scientific case for follistatin as an anti-fibrotic agent extends across multiple organ systems and disease models — providing converging evidence that its therapeutic effect is not tissue-specific but reflects a fundamental role in the biology of fibrosis itself.
Follistatin in Radiation-Induced Fibrosis
One of the most direct demonstrations of follistatin’s anti-fibrotic power comes from a 2017 study by Forrester et al. in PLOS ONE, which used a murine model of radiation-induced fibrosis. Follistatin-treated animals showed significantly improved leg extension (a measure of tissue mobility), reduced histological fibrosis, and reduced molecular markers of the fibrotic response compared to controls receiving radiation alone. The effect was maintained across a six-month treatment period — suggesting durable anti-fibrotic action rather than transient suppression.
The same group had previously demonstrated that follistatin levels are altered in fibroblasts from patients who developed severe radiation-induced fibrosis — and that Activin A, which follistatin antagonizes, is elevated in these cells. The implication: in fibrosis-prone tissue, the follistatin-to-Activin A balance is disrupted. Restoring that balance is therapeutic.
Follistatin in Renal Fibrosis
A study published in PLOS ONE (Ikeuchi et al.) demonstrated that recombinant follistatin prevented renal interstitial fibrosis in a rat model of unilateral ureteral obstruction — the standard model for progressive kidney fibrosis. Activin A expression was significantly upregulated in the fibrotic kidneys; follistatin administration blocked downstream SMAD signaling and halted fibrotic progression. Critically, the authors noted that the activin-follistatin axis operates in parallel with TGF-β — offering anti-fibrotic benefit that is not redundant with TGF-β blockade.
Follistatin in Muscle Fibrosis and Regeneration
Research published in the American Journal of Pathology (Zhu et al., American Journal of Pathology 2007) demonstrated that follistatin-overexpressing transgenic mice showed significantly greater muscle fiber regeneration and substantially less fibrosis formation following injury compared to wild-type animals. The mechanism involved both myostatin inhibition and enhanced neovascularization — improving blood supply to injured tissue, an effect with clear relevance to the vascular component of scleroderma.
Convergent Evidence: Follistatin’s Anti-Fibrotic Mechanism Across Tissues
- Radiation-induced fibrosis (skin/soft tissue): follistatin reduces fibrotic lesion development and improves tissue mobility (Forrester et al., 2017)
- Renal fibrosis: recombinant follistatin prevents collagen deposition and SMAD2/3 activation via Activin A blockade (Ikeuchi et al., PLOS ONE)
- Muscle fibrosis: follistatin-overexpressing animals show reduced fibrosis and enhanced regeneration post-injury (Zhu et al., Am J Pathol 2007)
- Inflammatory bowel disease: follistatin prevents fibrosis through inhibition of Activin A produced by cells responding to TGF-β (MDPI review, 2023)
- Across all models, the common thread: disrupting the Activin A / myostatin arm of the TGF-β superfamily reduces fibrosis independently of direct TGF-β blockade
Why Gene Therapy — Not a Protein Injection
Follistatin can be administered as a recombinant protein. But recombinant proteins have short half-lives — measured in hours to days. For a disease like scleroderma, where fibrotic signaling is continuous and self-amplifying, a short-lived protein injection cannot provide the sustained molecular inhibition required to meaningfully interrupt the cascade.
Gene therapy changes this calculus entirely. By delivering the genetic sequence for follistatin production to the patient’s own cells, gene therapy converts those cells into durable, endogenous follistatin factories. The patient’s biology sustains the therapeutic signal — not a vial, not a dosing schedule.
What Sustained Follistatin Expression Means for Scleroderma
- Persistent Activin A neutralization — the fibrogenic amplification loop is continuously disrupted, not periodically suppressed
- Continuous myostatin inhibition — anti-fibrotic tone is maintained in skin, muscle, and connective tissue without re-dosing
- Anti-inflammatory maintenance — reduced Activin A levels continuously dampen the immune activation that drives fibrotic relapse
- Protection during biological remodeling — the months following intensive treatment, when new tissue architecture is being established, remain protected
- Synergy with PSC exosome therapy — exosomes deliver transient anti-fibrotic reprogramming signals; follistatin gene therapy provides the durable anti-fibrotic foundation beneath them
Follistatin in the Context of Scleroderma’s Full Pathology
Scleroderma is not only a fibrotic disease. Its pathology has three interconnected arms: fibrosis, immune dysregulation, and vascular injury. Effective treatment must address all three. Follistatin gene therapy is the primary tool Blast Institute deploys against the fibrotic arm — the most therapeutically underserved of the three.
Fibrosis, immune activation, and vascular injury sustain each other. Immune cells — activated T cells, M2 macrophages, innate immune effectors — produce TGF-β and Activin A, feeding the fibrogenic cascade. Ischemic, poorly perfused tissue produces more inflammatory signals, which recruit more immune cells. Breaking the fibrotic loop with follistatin is not just anti-fibrotic — it is also, secondarily, anti-inflammatory.
How Follistatin Fits the Full Blast Scleroderma Protocol
- Follistatin gene therapy: primary anti-fibrotic intervention — sustained suppression of Activin A and myostatin across skin, lungs, and connective tissue
- PSC (pluripotent stem cell) IVs — daily: systemic reprogramming signals, immune modulation, endothelial support — addressing all three pathological arms
- VEGF-A gene therapy (local): vascular rescue at ischemic sites — sustained angiogenesis for approximately 8 months post-administration
- Local PSC exosome injections (twice weekly): concentrated anti-fibrotic and healing signals directly at skin and ulcer sites
- Ozone EBOO (weekly): immune reset, oxidative burden reduction — improving the biological environment for all other therapies
- The combination creates overlapping coverage: follistatin addresses what exosomes cannot sustain indefinitely; VEGF-A gene therapy addresses what exosomes cannot fully reach vascularity-wise
A Note on Timing: Why Follistatin Is Given Last
In the Blast Institute scleroderma protocol, follistatin gene therapy is administered on the final day of the 24-day treatment program. This is deliberate — and the sequencing matters biologically.
During the preceding three-and-a-half weeks, the tissue environment undergoes significant preparation: detoxification, immune recalibration via EBOO, progressive PSC exosome IV delivery, local injection treatment of fibrotic sites, and VEGF-A gene therapy vascularization. By the final day, the tissue is in a fundamentally different state than on Day 1: less inflamed, better perfused, more receptive to gene expression.
Administering follistatin gene therapy into a well-prepared tissue environment maximizes uptake, sustained expression, and biological effect. Gene therapy delivered into chronically inflamed, hypoxic, or immunologically overactivated tissue is substantially less effective than gene therapy delivered once the biological ground has been properly set. The protocol sequences are not arbitrary — they are mechanistically motivated.
What Patients Might Expect
Follistatin gene therapy is not a cure for scleroderma. Systemic sclerosis has a complex, multidecade natural history; no single intervention reverses established fibrosis overnight. What follistatin gene therapy offers — as part of a comprehensive protocol — is a meaningful, sustained shift in the fibrotic balance: less ongoing collagen deposition, more biologically stable tissue, and a longer-lasting anti-fibrotic effect than any recombinant protein could provide.
Clinically, this translates to several observable outcomes that build over time:
- Reduced progression of skin thickening in areas receiving ongoing treatment — potential improvement in modified Rodnan skin score over weeks to months
- Reduced fibrotic activity in pulmonary tissue where ILD is present — potentially slowing the rate of lung function decline
- Reduced myostatin-driven fibrosis in affected muscle tissue — supporting mobility and strength where systemic involvement is present
- Improved biological responsiveness to the PSC exosome therapies running concurrently — less fibrotic interference with regenerative signaling
- Anti-inflammatory downstream effects — contributing to reduced disease activity scores and systemic symptom burden
Because follistatin gene therapy produces sustained expression, its biological effects continue to develop and accrue for months following the treatment period. Patients who continue to improve at 8, 12, and 16 weeks post-protocol are, in part, experiencing the ongoing downstream consequences of maintained follistatin expression — not just the acute effects of the treatment course.
Could Follistatin Gene Therapy Be Part of Your Protocol?
The Blast Institute scleroderma protocol integrates Follistatin gene therapy alongside daily PSC (pluripotent stem cell) IVs, targeted exosome and VEGF-A local gene therapy, and ozone EBOO — addressing the fibrotic, vascular, and immune axes of systemic sclerosis simultaneously.
References
- Forrester HB, de Kretser DM, Leong T, Hagekyriakou J, Sprung CN. Follistatin attenuates radiation-induced fibrosis in a murine model. PLOS ONE. 2017;12(3):e0173788. doi:10.1371/journal.pone.0173788
- Forrester HB, Ivashkevich A, McKay MJ, Leong T, de Kretser DM, Sprung CN. Follistatin is induced by ionizing radiation and potentially predictive of radiosensitivity in radiation-induced fibrosis patient-derived fibroblasts. PLOS ONE. 2013;8(10):e77119. doi:10.1371/journal.pone.0077119
- Ikeuchi H, Kuroiwa T, Hiramatsu N, et al. Follistatin, an activin antagonist, ameliorates renal interstitial fibrosis in a rat model of unilateral ureteral obstruction. PLOS ONE. 2009;4(4):e5171. doi:10.1371/journal.pone.0005171
- Zhu J, Li Y, Shen W, et al. Relationships between transforming growth factor-β1, myostatin, and decorin: implications for skeletal muscle fibrosis. J Biol Chem. 2007;282(35):25852-25863; and: Follistatin improves skeletal muscle healing after injury and disease
- Distler JHW, Feghali-Bostwick C, Soare A, et al. Review: Frontiers in systemic sclerosis. Frontiers in Immunology — Ubiquitination in scleroderma fibrosis and its treatment. Front Immunol. 2018;9:2383. doi:10.3389/fimmu.2018.02383
- Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-567. doi:10.1172/JCI131139
- Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J. 2004;18(7):816-827.
- Macias-Silva M, et al. Reassessing the role of active TGF-β1 as a biomarker in systemic sclerosis: association of serum levels with clinical manifestations. Biomed Res Int. 2016;2016:6064830.
- Koumoutsakos P, et al. The role of TGF-β, activin and follistatin in inflammatory bowel disease. Diseases. 2023;11(2):15. doi:10.3390/diseases11020015
